Unknown

Dataset Information

0

Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency.


ABSTRACT: Tumor-specific cytotoxicity of drugs can be enhanced by targeting them to tumor receptors using tumor-specific ligands. Phage display offers a high-throughput approach to screen for the targeting ligands. We have successfully isolated phage fusion peptides selective and specific for PC3 prostate cancer cells. Also, we have demonstrated a novel approach of targeting liposomes through tumor-specific phage fusion coat proteins, exploiting the intrinsic properties of the phage coat protein as an integral membrane protein. Here we describe the production of Rhodamine-labeled liposomes as well as doxorubicin-loaded long-circulating liposomes targeted to PC3 prostate tumor cells via PC-specific phage peptides, as an extension of our previous studies. Targeting of labeled liposomes was demonstrated using fluorescence microscopy as well as flow cytometry. Targeting of doxorubicin-loaded liposomes enhanced their cytotoxic effect against PC3 cells in vitro, indicating a possible therapeutic advantage. The simplicity of the approach for generating targeted liposomes coupled with the ability to rapidly obtain tumor-specific phage fusion proteins via phage display may contribute to a combinatorial system for the production of targeted liposomal therapeutics for advanced stages of prostate tumor. From the clinical editor: This paper demonstrates targeting cytotoxic agents to tumor receptors using tumor-specific ligands. The authors describe the production of Rhodamine-labeled liposomes as well as doxorubicin loaded long circulating liposomes targeted to PC3 prostate tumor cells via PC-specific phage peptides. This approach may be especially relevant for advanced prostate tumors.

SUBMITTER: Jayanna PK 

PROVIDER: S-EPMC2952829 | biostudies-literature | 2010 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency.

Jayanna Prashanth K PK   Bedi Deepa D   Gillespie James W JW   DeInnocentes Patricia P   Wang Tao T   Torchilin Vladimir P VP   Bird Richard C RC   Petrenko Valery A VA  

Nanomedicine : nanotechnology, biology, and medicine 20100204 4


Tumor-specific cytotoxicity of drugs can be enhanced by targeting them to tumor receptors using tumor-specific ligands. Phage display offers a high-throughput approach to screen for the targeting ligands. We have successfully isolated phage fusion peptides selective and specific for PC3 prostate cancer cells. Also, we have demonstrated a novel approach of targeting liposomes through tumor-specific phage fusion coat proteins, exploiting the intrinsic properties of the phage coat protein as an int  ...[more]

Similar Datasets

| S-EPMC9388847 | biostudies-literature
| S-EPMC5706597 | biostudies-literature
| S-EPMC4097973 | biostudies-literature
| S-EPMC5618300 | biostudies-literature
| S-EPMC4753993 | biostudies-literature
2024-08-28 | PXD044287 | Pride
| S-EPMC3940962 | biostudies-literature
| S-EPMC7185221 | biostudies-literature
| S-EPMC8291752 | biostudies-literature
| S-EPMC8042446 | biostudies-literature